Emcure Pharma: Board approves FY26 Audited Results, ₹3.60 Dividend

Emcure Pharmaceuticals Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹3.60 per equity share (36%) subject to shareholder approval. Additionally, Dr. Mukund Gurjar was re-appointed as a Whole-time Director for one year starting August 28, 2026, and Mr. Satish Mehta was re-appointed as Managing Director for five years commencing April 1, 2027, both subject to member approval.